Company intelligence
Elion Medical Communications
Boutique Medical Writing & Medical Copywriting
About Elion Medical Communications
Elion is a boutique medical communications business. We deliver high-quality medical writing and healthcare communications for biopharmaceutical and medical device companies, and communications and healthcare advertising agencies worldwide. At Elion, we are passionate about disseminating the latest scientific research for cutting-edge therapies and medical devices. We distil complex science into eloquent medical communications that are delivered in a timely manner and with meticulous attention to detail. We work across the full spectrum of medical communications: - medical writing for peer-reviewed publications - promotional medical copywriting for healthcare professionals - educational materials for patients - data and reference checking - health content creation - marketing strategy and content planning - project management We love what we do and we do it with pride!
Verified activity
Signals from Elion Medical Communications
7 published signals
Research & Knowledge
Elion Medical Communications reported that the FDA cleared the first single-biomarker blood test capable of ruling in and ruling out amyloid pathology associated with Alzheimer disease.
Reported by Elion Medical Communications
Research & Knowledge
Elion Medical Communications reported that the FDA approved brepocitinib (Lisraya; Roivant), the first oral targeted treatment for adults with dermatomyositis.
Reported by Elion Medical Communications
Research & Knowledge
Elion Medical Communications reported that the Elecsys pTau217 test showed high agreement with amyloid positron emission tomography (PET) imaging and could provide a less invasive and more accessible option than PET scans or cerebrospinal fluid testing.
Reported by Elion Medical Communications
Research & Knowledge
Elion Medical Communications reported that Moderna and Merck announced positive phase 3 results for intismeran autogene, an individualised mRNA cancer therapy, in patients with resected, high-risk melanoma.
Reported by Elion Medical Communications
Research & Knowledge
Elion Medical Communications noted that the results represent the first positive phase 3 findings for an individualised mRNA-based cancer treatment.
Reported by Elion Medical Communications
Research & Knowledge
Elion Medical Communications noted that the Elecsys pTau217 test was developed by Roche in partnership with Eli Lilly and Company.
Reported by Elion Medical Communications
Research & Knowledge
Elion Medical Communications noted that in the phase 3 VALOR trial, a 30-mg daily drug dose improved muscle, skin and overall disease activity and met all key secondary endpoints.
Reported by Elion Medical Communications